^
    Back
    Association details:
    Biomarker:NF1 mutation
    Cancer:Melanoma
    Drug Class:PD1 inhibitor +
    MEK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMJ Case Rep
    Title:

    Ann Case Rep, an open access journal ISSN: 2574-77541 Volume 7; Issue 02 Research Article Cautious Addition of MEK Inhibitors to PD-1 Antibody Treatment in Patients with NRAS or NF1 Mutant Metastatic Melanoma Failing Initial Immunotherapy

    Published date:
    03/14/2022
    Excerpt:
    A retrospective analysis identified ten patients with initial progression on checkpoint inhibitor treatment, who continued PD-1 antibody treatment with the addition of low dose MEK inhibitors. Three patients had NF1 mutations, seven had NRAS mutations....An overall complete response rate of 60% was observed....Our results suggest a novel treatment option for patients with NF1- and NRAS-mutant melanomas who progress on initial immunotherapy.
    DOI:
    10.29011/2574-7754.100795